COMP <GO>
PLPC vs TMO // RETURN ON INVESTED CAPITAL (ROIC)
Preformed Line Products Company (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: PLPC 3
— TMO 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: TMO
LAST: $320.01 (-8.26%) • MKT CAP: $1.56B
roic
8.60%
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
roic
9.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PLPC VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PLPC | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 31.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 8.60% | 9.30% | -0.70 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.9x | 30.4x | -12.50 | PLPC | /valuation <GO> |
| Free Cash Flow Yield | 2.13% | 2.40% | -0.27 | TMO | /fcf-yield <GO> |
| Operating Margin | 8.20% | 17.40% | -9.20 | TMO | /operating-margins <GO> |
| Net Profit Margin | 5.30% | 15.10% | -9.80 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 12.70% | 3.90% | +8.80 | PLPC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.26% | 0.24% | +0.02 | PLPC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 4.50 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 24.8 | 62.9 | -38.13 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 37.2x | 36.3x | +0.90 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.56B | $262.22B | -$260.65B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PLPC REV | TMO REV | PLPC GROSS % | TMO GROSS % | PLPC FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $669.3M | $44.56B | 31.2% | — | $33.3M | $6.29B |
| FY 2024 | $593.7M | $42.88B | 32.0% | — | $52.8M | $7.27B |
| FY 2023 | $669.7M | $42.86B | — | — | $107.6M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PLPC // BETA —
TMO // BETA 0.94